Agilent to buy pathology software maker Proscia for $240 million

By Reuters News

Oct 13 (Reuters) - Agilent Technologies A.N said on Tuesday it would acquire pathology software maker Proscia for $240 million in cash, plus up to $30 million tied to future performance targets, as the laboratory equipment maker expands its push into AI-enabled diagnostics.


Here are some more details:

  • Privately held Proscia develops software that converts pathology slides into digital images that can be stored, reviewed and analyzed using artificial intelligence tools

  • Agilent said the acquisition would strengthen its pathology business and expand its presence in digital and AI-enabled diagnostics

  • The deal would provide Agilent access to a high-growth software business that generated more than $18 million in revenue over the past 12 months

  • The companies have worked together since 2022, when they entered a multi-year distribution agreement to offer a digital pathology system combining Agilent's pathology products with Proscia's software

  • The deal is expected to close early in Agilent's fiscal 2027

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.